2015 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals Awards Grants to Fund Prematurity Prevention Research

Recipients Selected by Independent Panel of Leading Experts in Maternal-Fetal Medicine and Obstetrics Annual Award Furthers AMAG’s Continued Commitment to Supporting Research to Improve the Health of Mothers and Babies WALTHAM, Mass., Dec. 22, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.... More > 

AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena(R)

WALTHAM, Mass., Nov. 23, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it responded to the U.S. Food and Drug Administration (FDA), providing the information and data requested in the Complete Response Letter (CRL) received by the company on November 18, 2015... More > 

AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena(R) (hydroxyprogesterone caproate injection)

WALTHAM, Mass., Nov. 18, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its application seeking approval for a single-dose vial of Makena (hydroxyprogesterone caproate injection) t... More > 

AMAG Pharmaceuticals to Participate in the Jefferies Autumn 2015 Global Healthcare Conference in London

WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference in London on Wednesday, November 18, 2015 at 3:20 p.m. GMT. The sessi... More > 

AMAG Pharmaceuticals Reports Third Quarter 2015 Financial Results

Achieves non-GAAP quarterly revenue of $103.5 million and adjusted EBITDA of $52.8 million Provides new updates on Makena next generation development programs Closes acquisition and initiates integration of Cord Blood Registry Conference call scheduled for 8:00 a.m. ET today WALTHAM,... More > 

AMAG Pharmaceuticals Announces Head-to-Head Phase 3 Clinical Trial Evaluating Feraheme(R) in Adults With Iron Deficiency Anemia

Clinical Trial Marks Step Forward on the Pathway to Pursue a Broader Feraheme(R) Label WALTHAM, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has commenced start-up activities for its head-to-head Phase 3 clinical trial evaluating the safe... More > 

AMAG Pharmaceuticals to Host Conference Call on November 3, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Nine Months Ended September 30, 2015

WALTHAM, Mass., Oct. 20, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the quarter and nine months ended September 30, 2015 before the U.S. financial markets open on Tuesday, November 3, 2015. The announc... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and growth prospects at the following investor conferences taking place in September 2015. FBR Secon... More > 

AMAG Pharmaceuticals Appoints Joseph Vittiglio as General Counsel and Secretary

WALTHAM, Mass., Aug. 24, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Joseph Vittiglio has joined the company as senior vice president, general counsel and secretary. In this position, Mr. Vittiglio will oversee all legal affairs of the company. "We are ... More > 

AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry

Expands company's growing maternal health business Transaction expected to be immediately accretive Company anticipates seamless integration and is well positioned for future acquisitions WALTHAM, Mass., Aug. 17, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (AMAG) (Nasdaq:AMA... More > 

AMAG Pharmaceuticals Announces Pricing of Private Offering of $500 Million of Senior Notes Due 2023

WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it has priced its offering of $500 million aggregate principal amount of 7.875% Senior Notes due 2023 (the "notes"). This represents a $50 million increase from the $450 million aggregate ... More > 

AMAG Pharmaceuticals Announces Closing of $231 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 472,500 shares ... More > 

AMAG Pharmaceuticals Announces Proposed Private Offering of $450 Million of Senior Notes Due 2023

WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it intends, subject to market and other considerations, to offer $450 million aggregate principal amount of Senior Notes due 2023 (the "notes"). AMAG intends to use the net proceeds fro... More > 

AMAG Pharmaceuticals Prices Public Offering of $201 Million of Common Stock

WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has priced its previously announced underwritten public offering of common stock consisting of 3,150,000 shares at a public offering price of $63.75 per share. Gross proceeds to AMAG fr... More > 

AMAG Pharmaceuticals Announces Proposed Public Offering of $200 Million of Common Stock

WALTHAM, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has commenced an underwritten public offering of approximately $200 million of its common stock. AMAG intends to grant the underwriters a 30-day option to purchase up to an additional 1... More > 

AMAG Pharmaceuticals Reports Record Second Quarter 2015 Financial Results

Achieves quarterly net product sales of $84.7 million and Non-GAAP adjusted EBITDA of $52.1 million Executes on two business development initiatives to further expand maternal health business Increases Non-GAAP Adjusted EBITDA and cash earnings guidance for 2015 Conference call schedule... More > 

AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio

Company Enters Into Option Agreement to Acquire Rights to Orphan Drug Candidate for Treatment of Severe Preeclampsia WALTHAM, Mass., July 22, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has entered into an agreement that grants AMAG an exclusive option ... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on July 23, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Three and Six Months Ended June 30, 2015

WALTHAM, Mass., July 17, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the three and six months ended June 30, 2015 before the U.S. financial markets open on Thursday, July 23, 2015. The announcement will... More > 

AMAG Pharmaceuticals to Acquire Cord Blood Registry

Expands Maternal Health Business with World's Largest Newborn Stem Cell Collection & Storage Company Transaction Expected to be Immediately Accretive Investor Conference Call Today at 8:00 AM Eastern Time WALTHAM, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (N... More > 

AMAG Pharmaceuticals Appoints Aaron Pelta as Vice President of Business Development

WALTHAM, Mass., June 9, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Aaron Pelta as vice president of business development and transactions, reporting to Melissa Klug, senior vice president of business development and strategy. Mr. Pelta comes ... More > 

AMAG Pharmaceuticals Launches Initiative to Raise Awareness of Preterm Birth and the Importance of a Full-Term Pregnancy

WALTHAM, Mass., June 9, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, a specialty pharmaceutical company, today announced that its maternal health division has launched a patient education initiative focused on raising awareness about preterm birth and the importance of bringing a pregnancy to full... More > 

AMAG Pharmaceuticals, Inc. to Participate in the Barclays High Yield Bond and Syndicated Loan Conference

WALTHAM, Mass., June 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Frank Thomas, AMAG's president and chief operating officer, will present at the Barclays High Yield Bond and Syndicated Loan Conference on Thursday, June 11, 2015 at 1:25 p.m. MDT in Colora... More > 

AMAG Pharmaceuticals Announces New Senior Management Appointments

Julie Krop, M.D. Named as New Chief Medical Officer WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced two appointments to its senior management team. Julie Krop, M.D., has joined the company as chief medical officer and senior vice president, ... More > 

AMAG Pharmaceuticals, Inc. to Participate in the Jefferies 2015 Healthcare Conference

WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3, 2015 at 3:00 p.m. ET in New York. The session will include a c... More > 

AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena(R) (Hydroxyprogesterone Caproate Injection)

Company Affirms 2015 Financial Outlook WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), today announced that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its manufacturing supplement seeking approval ... More > 

AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth

Company Announces Collaboration With NurseWise(R) to Help Enhance Adherence to Makena(R) (hydroxyprogesterone caproate injection) Therapy WALTHAM, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) a specialty pharmaceutical company, today announced its Lumara Health d... More > 

AMAG Pharmaceuticals, Inc. to Participate in the UBS Global Healthcare Conference

WALTHAM, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 3:00 p.m. ET in New York. The session will include a company ... More > 

AMAG Pharmaceuticals Reports Record First Quarter 2015 Financial Results and Increases Financial Guidance

First Quarter 2015 net product sales of $77.4 million and adjusted EBITDA of $47.4 million Company increases top and bottom line 2015 financial guidance Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

WALTHAM, Mass., April 29, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, and Frank Thomas, AMAG's president and chief operating officer, will participate in two upcoming investor conferences. The sessions will in... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on May 5, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2015

WALTHAM, Mass., April 22, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2015 before the U.S. financial markets open on Tuesday, May 5, 2015. The announcement will be followed b... More > 

AMAG Pharmaceuticals, Inc. to Participate in the 14th Annual Needham Healthcare Conference

WALTHAM, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Frank Thomas, AMAG's president and chief operating officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 8:00 a.m. ET in New York. The sess... More > 

AMAG Pharmaceuticals Announces New Management Appointments

Company Adds New External Affairs Function WALTHAM, Mass., April 1, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new management appointments which expand the company's ability to engage with external partners and stakeholders. Linda Lennox has joined the company... More > 

AMAG Pharmaceuticals Announces Closing of $201 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Option

WALTHAM, Mass., March 3, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 596,590 shares of common st... More > 

AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 35th Annual Healthcare Conference

WALTHAM, Mass., Feb. 27, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's president and chief executive officer, will present at the Cowen and Company 35th Annual Healthcare Conference on Monday, March 2, 2015 at 2:10 p.m. ET in Boston. Th... More > 

AMAG Pharmaceuticals Prices Public Offering of $175 Million of Common Stock

WALTHAM, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has priced its previously announced underwritten public offering of common stock consisting of 3,977,272 shares at a public offering price of $44.00 per share. Gross proceeds to AMAG fr... More > 

AMAG Pharmaceuticals Announces Proposed Public Offering of $125 Million of Common Stock

WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has commenced an underwritten public offering of approximately $125 million of shares of its common stock. AMAG intends to grant the underwriters a 30-day option to purchase up to an ad... More > 

AMAG Pharmaceuticals, Inc. to Participate in the 2015 RBC Capital Markets' Healthcare Conference

WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Frank Thomas, AMAG's executive vice president and chief operating officer, will participate in an analyst-led fireside chat at the 2015 RBC Capital Markets' Healthcare Conference on Tuesda... More > 

AMAG Announces Final Fourth Quarter and Year End 2014 Financial Results

Total fourth quarter revenue increased by 145% $73 million in pro forma fourth quarter 2014 product sales $153 million tax benefit recognized as a result of Lumara Health transaction Conference call scheduled for 4:30 p.m. ET today WALTHAM, Mass., Feb. 9, 2015 (GLOBE NEWSWIR... More > 

AMAG Pharmaceuticals, Inc. to Participate in the Leerink Global Healthcare Conference

WALTHAM, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's president and chief executive officer, will participate in an analyst-led fireside chat at the Leerink Global Healthcare Conference in New York, NY. The fireside chat... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on February 9, 2015 at 4:30 p.m. ET to Discuss Financial Results for the Quarter and Year Ended 2014

WALTHAM, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014 on Monday, February 9, 2015 after the close of the U.S. financial markets. The ann... More > 

AMAG Pharmaceuticals Provides Business Update and 2015 Financial Guidance

Integration of Lumara Health acquisition substantially complete Estimated pro forma fourth quarter 2014 product sales of $74 million 2015 sales guidance of $355 million represents +300% increase over 2014 sales WALTHAM, Mass., Jan. 11, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. ... More > 

AMAG Pharmaceuticals, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will provide an update on the company followed by a breakout session at the 33rd Annual J.... More >